3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
40
Lung Neoplasms
15
Neoplasms
2
NSCLC
2
Breast Neoplasms
2
Brain Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor, Adult
1
Sexual Dysfunction, Physiological
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non-Small Cell Lung Cancer With EGFR Mutation
1
Non Small Cell Lung Cancer Metastatic
1
NSCLC Patients With Brain Metastasis
1
Multiple Endocrine Neoplasia Type 2a
1
Mesothelioma
1
Meningeal Carcinomatosis
1
Lung Cancer Metastatic
1
Locally Advanced or Metastatic Non-squamous NSCLC
1
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
1
Lethal Congenital Contracture Syndrome 2
1
Head and Neck Neoplasms
1
Eunuchism
1
Erectile Dysfunction
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Advanced Solid Tumors
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
25
Cisplatin
17
Carboplatin
13
Radiotherapy
12
Cetuximab
9
Blood Specimen Collection
9
Docetaxel
8
Paclitaxel
7
Fluorouracil
7
Drug Therapy
7
toripalimab
6
tislelizumab
4
nimotuzumab
4
atezolizumab
4
Radiation
4
Chemoradiotherapy
4
fludarabine
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Standard of Care
3
Radiotherapy, Intensity-Modulated
3
Cyclophosphamide
3
Biopsy
3
130-nm albumin-bound paclitaxel
3
cemiplimab
2
avelumab
2
X-Rays
2
Tocopherols
2
Tiragolumab
2
Therapeutics
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Head and Neck Neoplasms
×
osimertinib
×
Clear all
NCT05647122
2026-05-11
EGRET
AstraZeneca
Phase 1
Recruiting
403 enrolled